Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma

PLoS One. 2012;7(11):e48694. doi: 10.1371/journal.pone.0048694. Epub 2012 Nov 19.

Abstract

Clear-cell renal cell carcinoma (RCC) is, in most cases, caused by loss of function of the tumor suppressor gene von Hippel-Lindau, resulting in constitutive activation of hypoxia-inducible factor (HIF)-1α and expression of hypoxia-induced genes in normoxic conditions. Clear-cell RCC cells are characterized histologically by accumulation of cholesterol, mainly in its ester form. The origin of the increased cholesterol remains unclear, but it is likely explained by an HIF-1α-driven imbalance between cholesterol uptake and excretion. Here, we showed that expression of the very low-density lipoprotein receptor (VLDL-R) was significantly increased in clear-cell RCC human biopsies compared with normal kidney tissue. Partial knockdown of HIF-1α in clear-cell RCC cells significantly reduced the VLDL-R expression, and knockdown of either HIF-1α or VLDL-R reduced the increased lipid accumulation observed in these cells. We also showed increased uptake of fluorescently labeled lipoproteins in clear-cell RCC cells, which was significantly reduced by knockdown of HIF-1α or VLDL-R. Taken together, our results support the concept that the pathological increase of HIF-1α in clear-cell RCC cells upregulates VLDL-R, which mediates increased uptake and accumulation of lipids. These results explain the morphological characteristics of clear-cell RCC, and open up novel possibilities for detection and treatment of clear-cell RCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell / metabolism*
  • Carcinoma, Renal Cell / pathology
  • Cell Line, Tumor
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Kidney Neoplasms / metabolism*
  • Kidney Neoplasms / pathology
  • Lipid Metabolism*
  • Receptors, LDL / metabolism*

Substances

  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Receptors, LDL
  • VLDL receptor

Grants and funding

This work was supported by the Swedish Research Council (contracts K2011-65X-12563-14-66)(www.vr.se), the Swedish Heart-Lung Foundation (contract 200090683) (www.hjart-lungfonden.se), Novo Nordisk Foundation (contract R177-A14864) (www.novonordiskfonden.dk/en), the Swedish Foundation for Strategic Research (contract A3 05:188) and the EU-funded projects ETHERPATHS (Contract FP7-KBBE-222639) and LipidomicNet (Contract HEALTH-2007-2.1.1-6). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.